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Abstract 
We formulate the dynamical model for the anti-tumor immune response based on intercellular 
cytokine-mediated interactions with the interleukin-2 (IL-2) taken into account. The analysis 
shows that the expression level of tumor antigens on antigen presenting cells has a distinct 
influence on the tumor dynamics. At low antigen presentation a progressive tumor growth takes 
place to the highest possible value. At high antigen presentation there is a decrease in tumor size to 
some value when the dynamical equilibrium between the tumor and the immune system is 
reached. In the case of the medium antigen presentation both these regimes can be realized 
depending on the initial tumor size and the condition of the immune system. A pronounced 
immunomodulating effect (the suppression of tumor growth and the normalization of IL-2 
concentration) is established by considering the influence of low-intensity electromagnetic 
microwaves as a parametric perturbation of the dynamical system. This finding is in qualitative 
agreement with the recent experimental results on immunocorrective effects of centimeter 
electromagnetic waves in tumor-bearing mice.  
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1. Introduction 
A theoretical investigation of cancer growth under immunological activity has a long 
history (see, e.g., [1] and the references therein). Most of the known models consider 
dynamics of two main populations: effector cells and tumor cells [27,44]. Some models 
include the dynamics of certain cytokines [3,10,24]. An important issue of these studies is a 
variation of the concentration of cytokines during the disease. As is known, tumor growth 
results in imbalance between the production and the regulation of cytokines as well as in the 
reduction of the corresponding receptors thus leading to the suppression of the immunological 
activity. Therefore, the methods for enhancement of both the anti-tumor resistance and the 
general condition of the immune system are of current clinical and theoretical interest. One of 
them refers to the use of cytokines, in particular interleukin-2 (IL-2) [16,18,21,22]. 
Interleukin-2 is considered as the main cytokine responsible for the proliferation of cells 
containing IL-2 receptors and their following differentiation [48]. IL-2 is mainly produced by 
activated CD4+ T-cells. There are many evidences that IL-2 plays an important role in 
specific immunological reactions to alien agents including tumor cells [28,38,48]. Clinical 
trials also show positive treatment effects at low doses of IL-2 [18, 40—42]. At the same 
time, at high doses treatment with IL-2 may cause serious hematologic violations revealed by 
anemia, granulocytopenia, thrombocytopenia, and lymphocytosis.  
The first detailed model of the anti-tumor immune response with IL-2 taken into account 
was proposed by DeBoer et al. [10]. It contains eleven ordinary differential equations and five 
algebraic equations and was used to study the role of macrophage- T lymphocyte interactions 
that are involved in the cellular immune response. The analysis shows a possibility for both 
tumor regression and uncontrolled tumor growth depending on “the degree of antigenicity” 
(the initial size of the T lymphocyte precursor populations that can be stimulated upon 
introduction of specific antigen).  
Afterward, Kirschner and Panetta proposed a simpler model where only three main 
populations were considered: the effector cells, the tumor cells, and IL-2 [24]. The model 
allows them to study effects of immunotherapy based on the use of cytokines together with 
adoptive cellular immunotherapy (ACI). ACI refers to the injection of cultured immune cells 
that have anti-tumor reactivity into tumor bearing host [24]. It was found that without 
immunotherapy the immune system is unable to clear the tumor with low antigenicity (a 
measure of how different the tumor is from ‘self’), while for highly antigenic tumors 
reduction to a small dormant tumor takes place. When tumor exhibits average antigenicity, 
stable limit cycles were observed. This implies that the tumor and the immune system 
undergo oscillations.  
Further, in the framework of the model by Kirschner and Panetta [24], Arciero et al. 
considered a novel treatment strategy known as small interfering RNA (siRNA) therapy [3]. 
The model [3] consists of a system of nonlinear, ordinary differential equations describing 
tumor cells, immune effectors, the immuno-stimulatory and suppressive cytokines IL-2 and 
TGF-β as well as siRNA. TGF-β suppresses the immune system by inhibiting the activation 
of effector cells and reducing tumor antigen receptors. It also stimulates tumor growth by 
promoting angiogenesis. siRNA treatment suppresses TGF-β production by targeting the 
mRNA that codes for TGF-β, thereby reducing the presence and effect of TGF-β in tumor 
cells. The model predicts conditions under which siRNA treatment can be successful in 
returning TGF-β producing tumors to its passive, non-immune evading state. 
Recently, a recovery of IL-2 production after the exposure of tumor-bearing mice to low-
intensity centimeter waves was experimentally observed [17]. This indicates that exposure to 
centimeter electromagnetic waves may be used for an enhancement of the anti-tumor immune 
response. In experiments, solid tumors were formed by means of hypodermic transplantation 
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of the ascitic Ehrlich’s carcinoma cells. Notice that previous investigations of effects of low-
intensive microwave radiation also show the immunomodulating effects at certain frequency 
ranges and intensities (see, e.g., [9,26]). These findings stimulate our interest to study the 
influence of weak centimeter electromagnetic waves on tumor-immune dynamics. Actually, 
the influence of EMR depends on the type of radiation, a distance from the radiation source 
(far-field versus near-field exposure conditions), frequency range, sizes and shapes of objects. 
Evidently, it is a hard problem to take properly into account all these factors within any 
theoretical description. In this paper, we offer a reasonable phenomenological approach. 
First of all, we formulate an appropriate mathematical model of anti-tumor immune 
response with the interleukin-2 taken into account (Sect. 2). To this end, we follow the 
scheme of intercellular cytokine mediated interaction in cellular immune response proposed 
by Wagner et al. in [48] which was modified by taking into account co-stimulatory factors 
such as B7/CD28 and CD40/CD40L instead of interleukin-1 (see, e.g., [28,38]). The analysis 
of the model is presented in Section 3. In Section 4 we discuss a possibility of 
immunomodulating effect of weak radiofrequency electromagnetic radiation (RF EMR) 
considering the influence of irradiation as a parametric perturbation of the initial dynamical 
system. 
2 Model 
We describe the dynamics of cellular populations participating in formation of cytotoxic 
effector cells and cytokines mediating these reactions in accordance with a scheme presented 
in Figure1. Some important remarks should be done. Generally, the population of T cells is 
divided into two subpopulations: helper T cells (HTL) that express marker CD4 on their 
surface and cytotoxic T cells (CTL) that express CD8 marker [38]. CTL specifically 
recognize complexes of antigen (AG) with MHC (major histocompatibility complex, in 
human being — HLA human lymphocyte antigens) class I on the surface of alien or tumor 
cell and destroy them through this interaction. In contrast to CTL, HTL recognize complexes 
AG-MHC II on tumor cell and play a regulatory role in the expansion of CTL. 
In order to stimulate both HTL and CTL against tumor antigen, it must be presented via 
MHC class I and II molecules expressed by professional antigen-presenting cell (APC). There 
are three main types of professional antigen-presenting cells: dendritic cells, macrophages and 
B cells. Dendritic cells and, to a lesser extent, macrophages have the broadest range of antigen 
presentation and are probably the most important APC. They exist as immature (iAPC) and 
mature (mAPC) forms.  
The dynamical equations for immature APC (m) and mature APC (M) are written as  
 mTmVm mmm γ−β−= , (1) 
 MmTM Mm β−γ= . (2) 
In (1) Vm characterizes a steady inflow of iAPC from monocytes which in turn are formed 
from stem cells in the bone marrow. The second term describes iAPC death rate. iAPC 
phagocytose AG, degrade it, and present their fragments at the plasma membrane using MHC 
molecules upon maturation. Simultaneously, they express co-stimulatory molecules such as 
B7 and CD40 [28,38]. Thus iAPC become mature APC (mAPC) expressing both complexes 
AG-MHC-I and II as well as co-stimulatory molecules which are recognized by specific 
receptors on T cells. The rate of transfer from iAPC to mAPC is described by the third term in 
(1) where T is the number of tumor cells. The concentration of antigen is supposed to be 
proportional to the number of tumor cells. The production rate of mAPC in (2) is equal to the 
rate of transfer. The mAPC death rate is described by the second term. 
Dynamics of HTL precursors (H) and IL-2 (I2) is chosen to be 
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 HVH HH β−= , (3) 
 222
~ TILIHMI TLH γ−α−γ= . (4) 
In (3) VH characterizes the inflow of HTL precursors (HTLP) from stem cells. The second 
term shows the death rate of HTLP. As a result of interaction between complex AG-MHC-II 
on mAPC and HTLP (see signal 1 in Figure1) in the presence of a number of co-stimulatory 
molecules CD40 (signal 2), activated HTLP produce lymphokines (including IL-2) and 
corresponding receptors. A similar production is observed when mAPC presents antigen with 
MHC-I molecule to cytotoxic T cells precursor (CTLP) in the presence of co-stimulatory 
molecules B7 binding to CD28 markers. The interaction between IL-2 and corresponding 
receptors on activated T lymphocyte precursors (HTLP and CTLP) induces their proliferation 
and differentiation into mature T lymphocytes (HTL and CTL). In order to simplify 
consideration we omit an equation for HTL activated by tumor antigen assuming that the 
proliferation of HTL in response solely to IL-2 is absent. This is based on the fact that the 
levels of expression of IL-2 receptors on HTL are substantially lower than those observed on 
CTL [30]. Hence, the new AG stimulation is required to support the proliferation of HTL. In 
addition, our analysis shows that the exclusion of the equation for activated HTL does not 
influence the tumor growth dynamics within the model. Thus, HTLP stimulated by mAPC are 
assumed to perform the role of IL-2 producers. We suggest that the concentration of IL-2 
grows linearly with HTLP and mAPC (first term in (4)). As long as IL-2 is a short-distance 
cytokine, it is supposed that target cells CTL (L)) effectively consume IL-2. For this reason, 
we neglect the term presenting loss rate of IL-2. We also consider in (4) the diminution of IL-
2 molecules (forth term) as a result of interaction with prostaglandins, immuno-suppressing 
substances which both suppress the production of IL-2 and directly destroy its molecules [37]. 
Notice that concentration of prostaglandins is supposed to be proportional to the number of 
tumor cells T. 
Let us formulate the dynamical equation for cytotoxic T cells (L). Similarly to 
[7,13,27,31,32,34] we suggest that CTL-tumor cell interaction follows enzymatic kinetics, 
that is 
 L + T 
←→
−
γ
γ
L
L
 LT → LY
~
 P + L. 
Indeed, CTL can be bound to tumor cell either reversibly (forward and back reactions with the 
corresponding rates γLLT and γ-L(LT), tumor cells are not ‘suffering’) or irreversibly (LT 
complex is formed) inducing cell death [2,38]. CTL kill tumor cells via one of two main 
mechanisms. The first one is based on the secretion of perforines. Perforines are embedded 
into the membrane of tumor cells and form pores thus clearing a way for penetrating water. 
LT complex dissociates into ‘doomed’ tumor cell (P) and CTL (L) with a rate Lγ~ (LT). Tumor 
cell swells and gets killed while CTL looks for the new target. The second mechanism 
involves programmed cell death (apoptosis) through the Fas/Fas ligand pathway. Thus, we 
introduce an additional equation for “substratum-enzyme complex” (LT) and the equation for 
immune cells reads 
 )(~)(2 LTLTLTLILVL LLLLLL γ+γ+γ−α+β−= −  (5) 
 ( ) )(~)( LTLTLTLT LLL γ−γ−γ= −
.
. (6) 
In (5) VL characterizes the constant inflow of CTL into the tissue. The second term 
describes the death rate of CTL. The population of CTL increases due to its proliferation in 
the presence of IL-2 (the third term in (5)). The remaining terms in (5) describe the CTL-
tumor cell interactions. As is seen, equation (5) describes an expansion of cytotoxic T cells in 
the presence of IL-2 without antigen stimulation. A similar consideration was presented 
within the programmed proliferation model by Wodarz and Thomsen in [50]. They suggested 
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that the interaction with infected cell transfer CTLP to population of proliferating CTL, which 
undergo a limited number of divisions without AG stimulation before the differentiation into 
effector cells. Thus, they use separate equations for population of CTLP, effector cells and n 
intermediate populations of CTL that passed i = 1,2, … n divisions. 
Finally, the population of tumor cells is described by  
 )(ln LTTLTTT LL
T
T
T −γ+γ−
α
β
α−= . (7) 
Notice that some studies include exponential law to describe tumor growth (see, e.g., 
[13,43,44]). When tumor cells grow in conditions of an interior competition one has to use the 
limiting growth laws, for instance logistic or Gompertzian [24,27,46]. In our model, we prefer 
to choose the Gompertzian law (the first term in (7)). This allows us to avoid the regime of 
tumor autoregression under immunological activity only. Such outcome would contradict 
numerous clinical experiments. As another reason, clinical and experimental observations 
show that the growth of some tumors is fitted by the Gompertzian function [19,33]. 
It should be mentioned that we do not consider here processes of angiogenesis (vascular 
growth), invasion and metastasis, which are of importance at late (III-IV) stages of the tumor 
growth. Actually, inclusion of processes of vascular growth and invasion requires serious 
extension of the model to describe dynamics of cytokines, enzymes and other components 
regulating these processes. Besides, it would be necessary to take into account spatial 
migration of cell populations during the process of invasion (see, e.g., [8]). Therefore, the 
system (1)—(7) is valid for the description of early stages of the tumor growth when the 
processes of angiogenesis, invasion and metastasis are not of critical importance. This model 
allows us to study the different regimes of early immunological activity. However, the 
formulated model consists of seven differential equations and a great number of model 
parameters. This makes it difficult to analyze even qualitatively. Therefore, trying to decrease 
the number of the model equations we will make some simplifying assumptions. 
First of all, for lingering diseases one can consider (LT)(t) as rapid variable. In other 
words, it rapidly reaches its stationary value which remains fixed during the time of the 
immune response. In this case, 0)(
.
=LT  and one obtains from (6) that 
)~/()( LLL LTLT −γ+γγ= . Substituting this expression in (5) and (7) one finally gets  
 LLIVL LLL β−α+= 2 , (8) 
 LTTTT L
T
T
T γ′−
α
β
α−= ln , (9) 
where )~/(~ LLLLL γ+γγγ=γ′ − . 
Let us assume that m(t), M(t), and H(t) are also in quasi steady states. In this case, 
equation (4) is written as 
 222
~2 TILI
KT
T
I TL
T
I γ−α−
+
α
=

, (10) 
where expressions for 
2Iα = γHVHVm/(βHβM) and TK =βm/γm follow from the equations ,0=m  
0 =M , and 0=H . 
Finally, the model becomes much simpler and contains only three main equations (8)—(10). 
Nevertheless, it incorporates the most important modern concepts of tumor-immune dynamics 
including the influence of IL-2 dynamics. The first two equations resemble the famous 
predator-pray model with tumor cells as ‘victims’. As is seen, the growth rate of ‘predators’ 
(CTL population) depends on the concentration of IL-2. In (8) we take into account the steady 
influx of CTL likewise some other considerations (see, e.g., [27,44]). Let us mention once 
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more that, at first glance, such description ignores the preliminary antigen stimulation. In fact, 
this stimulation is considered in (10) through the first term where IL-2 production depends on 
tumor size. We use the hyperbola which allows us to take into account a limitation in 
stimulation of the immune system by the growing tumor. At small T the growth rate is linear 
in tumor size while for big tumor (T >> KT) it tends to a constant value. The last term in (10) 
reflects a destruction of IL-2 by metabolic products of tumor cell which are proportional to 
the concentration of tumor cells [37]. 
2.1. Parameter set 
An important question is the choice of parameters. The dynamics of disease is very 
sensitive to parameters in equations (8)—(10). The used values are given in Table 1. Some 
values were estimated by using the available experimental data. In particular, the growth 
parameters of ascitic Ehrlich carcinoma αT and βT were obtained from the experimental data 
found in Lobo’s results where the Ehrlich ascites tumor cell line was cultured in vitro [29]. 
Using the least-squares method, we fitted the experimental data by Gompertzian curve. The 
death rate of CTL was estimated using the relation βL = 1/τ where τ is their known average 
lifetime. The rate of steady inflow of CTL was calculated from the relation VL = βLLfree where 
Lfree (the number of CTL capable to recognize carcinoma specific antigen in the organism 
without tumor) was estimated to be about 2.4×105 cells using the data for the number of 
CD8+ T cells in spleen of mice [5] and a percent value of T cells specific for tumor type [14]. 
For the rest of parameters we chose values most appropriate to our model. Current medical 
literature and sensitivity analysis (see subsection 3.3) allow us to conclude that the 
corresponding interactions are of importance in the description of immune response. 
3. Non-dimensionalization, steady state and sensitivity analysis 
3.1. Scaling 
For convenience, let us introduce dimensionless variables and parameters as follows: 
 T ′  = T/T0, L′  = L/L0, 2I ′  = I2/I20, and t ′  = t/τ where T0 = 2.6×10
6
 cells, L0 = 106 cells, 
I20 = 2×107 cells, and τ = 1−βL . The time-scale factor τ is chosen on the basis that the mean 
lifespan of CTL is about three days and the similar time is needed for the proliferation of CTL 
and IL-2 production [6,11]. 
Dropping primes for notational clarity, one finally obtains the following scaled model 
 TLh
h
ThThT 3
1
2
1 −−= ln , (11) 
 LLIhhL −+= 254 , (12) 
 2827
9
6
2 TIhLIhhT
Th
I −−
+
=

, (13) 
where h1 = αT/βL, h2 = βTT0/βL, h3 = Lγ′ L0/βL, h4 = VL/βLL0, h5 = Lα I20/βL, h6 = 2Iα /βLI20, 
h7 = Lα~ L0/βL, h8 = γTT0/βL and h9 = KT/T0. 
3.2. Steady states analysis  
Let us perform a steady state analysis of the system (11)—(13) by using isoclines. We 
consider the phase plane TL to reflect interactions between two main populations: tumor cells 
and CTL. In this case, the equations for main isoclines read  
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 0658794 =+++− TLhhThLhhTLh ))()(( , (14) 
 0=T , 
1
2
3
1
h
Th
h
h
L ln−= . (15) 
The fixed points are situated at the intersections of isoclines (14) and (15). Our analysis shows 
that the system (11)—(13) has an unstable point (0, h4, 0) for any choice of parameters. This 
point lies at the intersection of isoclines (14) and T = 0.  
We consider 
2I
α  as a varying parameter to present possible model outcomes. In fact, 
2I
α  
features the antigen presentation. Indeed, it is proportional to γH which characterizes the 
probability of interaction between mAPC and HTLP. In turn, this probability depends on the 
expression of AG-MHC-II complexes on the surface of APC. The antigen presentation by 
APC is considered as one of important factors in the immune response to tumor. Tumor cells 
develop a number of mechanisms to escape recognition and elimination by immune system. 
One of them is the loss or down-regulation of MHC class I and II molecules presenting AG 
on tumor cells. This mechanism prevents lymphocytes from recognizing tumor cells [38]. If 
tumor cells do not possess antigens of MHC-II, an activation of helper T cells depends on the 
processing of tumor antigens by APC.  
A bifurcation diagram for the dimensionless parameter h6 is presented in Figure 2 where 
the function h6(T) is obtained by substitution of L from (15) into (14). As is seen, there are 
three bifurcation points. Therefore one can distinguish four main dynamical regimes. For a 
low antigen presentation (h6 < h6min) the system (11)—(13) has two fixed points: a saddle 
point (0, h4, 0) and an improper node (T3, L3, I23). This means that the population of tumor 
cells is able to escape from the immune response under IL-2 deficiency. The tumor grows and 
the immune system becomes suppressed. In the region h6min < h6 < h6max corresponding to a 
medium antigen presentation there appear two additional fixed points: a stable spiral (T1, L1, 
I21) and an unstable saddle (T2, L2, I22). Therefore different regimes can exist depending on the 
initial conditions. First, when the initial size of CTL population is sufficiently large the 
regression of tumor up to a small fixed size takes place (the dynamical equilibrium between 
tumor and immune system is reached). In this case, the tumor manifests itself via the excited 
immune system. Second regime appears when initial number of CTL is not large enough to 
drive the system at the dynamical equilibrium point (T1, L1, I21), which is a stable spiral. Thus, 
the tumor grows to a highest possible size defined by conditions of restricted feeding. The 
dynamical equilibrium between the tumor and the immune system is reached at the fixed 
point (T3, L3, I23) that is an improper node. In the case of a high antigen presentation (h6 > 
h6max) the fixed points (T2, L2, I22) and (T3, L3, I23) disappear. As a result, there are two fixed 
points: a saddle point (0, h4, 0) and a stable spiral (T1, L1, I21). In this case, a decrease in tumor 
size is found when the equilibrium between the tumor and the immune system is established 
(dormant tumor). Finally, let us discuss the case of a high antigen presentation level (h6 > HB) 
when Hopf bifurcation occurs and stable spiral (T1, L1, I21) becomes unstable spiral. Integral 
curves tend to stable limit cycle and, accordingly, we observe oscillations in small tumor size, 
number of CTL and the concentration of IL-2. This means that the immune system is able to 
prevent tumor from uncontrolled growing. This also corresponds to the dormant tumor. 
3.3. Sensitivity analysis 
The sensitivity analysis has been carried out to test which components of the model (8)—
(10) contribute most significantly to tumor dynamics. We altered each parameter (taken 
separately) from its estimated value (Table 1, M1) by 1% and calculated the change in the 
tumor size after 30 days. The results are shown in Figure 3. As is seen, the system is most 
sensitive to the tumor growth rate αT and the CTL death rate βL.  
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We found lesser (yet remarkable) sensitivity to the following parameters: the rate of 
tumor cells inactivation by CTL Lγ′ , the CTL proliferation rate αL, the antigen presentation 
2I
α  as well as the rate of inactivation of the IL-2 molecules by prostaglandins γT. The system 
is of little sensitivity to the consumption of IL-2 Lα~  and the half-saturation constant KT. What 
is important for our consideration, the parameters Lγ′  and 2Iα  belong to the second group. 
This means that even a small variation of either the antigen expression on tumor cells or the 
antigen presentation by APC will markedly affect tumor dynamics. Based on both bifurcation 
and sensitivity analysis we will associate the region I in Figure 2 with a weak immune 
response, and the region II with the strong immune response. The region III is associated with 
the case of dormant tumor when the immune system is able to handle the tumor size. 
In conclusion, it is interesting to examine how alterations of either αT or Lγ′  affect the 
model regimes. Let us introduce a variable T~  
 )exp(~
1
43
2
1
h
hh
h
hT −= , (16) 
which is a zero of the function h6(T) (see Figure 2). The bifurcation diagram for 
dimensionless parameters h6 versus h1 is shown in Figure 4(a). As is seen, both h6min and h6max 
increase with h1. For small rate of tumor growth, the region II diminishes and T
~
 decreases in 
(16). In this case, the region II becomes inessential and the dynamical behavior is determined 
by the regions I and III. The final tumor size in the region I becomes small in comparison 
with the case of rapidly growing tumor. Besides, in the region III HB increases with h1 (see 
Figure 4(a)). This means that slowly growing tumors are not able to evade even weak immune 
supervision. In the case of high rate of tumor growth the region II markedly extends and T~  
increases. Therefore, a high antigen presentation is required to reach the region III 
corresponding to dormant tumor and the possibility of tumor remission decreases with 
increasing tumor growth rate. In other words, the rate of tumor growth can give warning of 
malignance. 
The next important characteristic determining the outcome of the disease is the 
expression of AG-MHC-I complexes on the surface of tumor cells. In our consideration, a 
level of this expression is characterized by the parameter Lγ′ . Figure 4(b) shows the 
bifurcation diagram for h6 versus h3. As is seen, with h3 increasing the region II vanishes and 
T~  descends in (16). This means that the immune system is able to handle cancer. For small 
antigen expression, the strength of the immune response depends on the level of antigen 
presentation (h6). Therefore, for tumors with poor immunogenicity (low antigen expression) a 
high antigen presentation on APC can be responsible for the strong immune response. 
4. Immunocorrective effects of radiofrequency electromagnetic waves 
In this section we discuss a possible way to take into consideration the influence of low-
intensity electromagnetic microwaves within our model. Since the main effects have a 
complex nonlinear dependence on frequency, intensity, and other characteristics of EMR we 
suggest using a phenomenological approach. To justify our consideration let us present an 
overview of some important biological and physical aspects.  
Above all, we would like to stress that our consideration is restricted to the frequency 
range 8—18 GHz and a low incident power ~1 µW/cm2 because namely these characteristics 
of EMR were explored in recent experiments by Glushkova et al. [17]. Two important 
experimental findings should be mentioned. First, both the concentration of IL-2 in the serum 
of tumor-bearing mice and the production of this cytokine were found to be normalized after 
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exposure to microwaves. Second, the yield of heat shock proteins-72 (HSP-72) by spleencytes 
was observed in both healthy and tumor bearing mice exposed to radiation. The last finding is 
rather surprising and could indicate the presence of cellular stress response under the 
exposure. As is known, HSP play a role of “molecular chaperones” binding to and stabilizing 
partially unfolded proteins, thus providing the cell with protection. However, our estimation 
of the specific absorption rate (SAR) by using the empirical model by Durney et al. [12] gives 
~0.5 mW/kg for mouse. In experiments [17] mice were exposed to microwaves daily during 
20 days. The duration of the exposure was 1.5 hour. It is easy to estimate that during 1.5 hours 
only 2.7 J/kg of electromagnetic energy is absorbed. Therefore, the intensity level used in [17] 
is not sufficient for occurring conformation changes. In this case, the question arises: how to 
explain the appearance of HSP? Unfortunately, this is an open problem yet. Nevertheless, 
some existing ideas allow us to suggest the following scenario.   
In accordance with a hypothesis of the resonant absorption the electromagnetic energy in 
microwave (RF) range is absorbed mainly by aqueous environment. Therefore, the observed 
HSP production could be caused by free radicals in water (see, e.g., [20]). According to 
[4,47], free radicals may be produced from water (H2O) by any process that moves clusters of 
water relative to each other, for instance, the mechanical vibration 
(H2O)n(H2O <- - - -H—OH - - - ->OH2)(H2O)m → (H2O)n(H2O + 
radicalsfree
OHH ⋅⋅+ + OH2)(H2O)m  
2 OH⋅ →H2O2. 
In the case of low-intensive EMR, small mechanical vibrations of water clusters may result 
from non-radiating transitions of excited molecules. It should be stressed that at low incident 
power of EMR very low concentrations of free radicals will be formed. This is very important 
for getting the therapeutic effect because the perturbations in concentrations of free radicals 
should not exceed physiological levels. In this case, mechanisms of natural antioxidant 
defense are able to reduce oxidative stress. For example, melatonin is found to mediate the 
inactivation of free radicals by stimulating some important antioxidative enzymes [36]. 
Besides, melatonin is able to activate helper T lymphocytes thereby increasing the production 
of IL-2 and IFN-γ [15]. This could explain the experimentally observed recovery of IL-2 
production. There is also a different possible mechanism of antioxidant defense when free 
radicals activate such nucleus transcription factors as NFAT and NFκB (see [45] and the 
references therein). Indeed, NFκB and NFAT induce the expression of the antioxidant genes 
[20,45]. It has been recently observed in experiment that the production of NFκB actually 
increases as a result of exposure to weak RF EMR [23]. Notice that NFAT and NFκB are 
transcriptional regulators of the IL-2 gene [25,39]. Therefore, additionally to the antigen 
stimulation, these factors can be also activated by EMR-induced free radicals thereby 
enhancing the production of both IL-2 and very likely IFN-γ. 
Let us revert to the model. In order to reflect the influence of EMR we assume to vary 
two basic model parameters Lγ′  and 2Iα . Let us remind that Lγ′  represents the destruction rate 
of tumor cells by CTL. With growing production of IFN-γ the expression of molecules MHC 
class I and II on tumor cells increases thus enhancing their recognition by CTL [35]. In 
addition, HSP-72 also mediate up-regulation of AG- MHC-I complexes on surface of tumor 
cells [49]. Therefore, the parameter Lγ′  should be increased for taking into account the 
radiation. The parameter 
2Iα  characterizes the antigen presentation. Notice that for big tumor 
sizes 
2Iα  determines the rate of the IL-2 production that enhanced by the melatonin. 
Therefore 
2Iα  also should be increased. We assume that these parameters remain time-
independent and merely increase to the new constant values expLγ′  and exp2Iα . In other words, 
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we suggest that an influence of EMR is effective during all the time between exposures. 
Unfortunately, it is impossible to extract the values of expLγ′  and exp2Iα  from existing 
experiments. Therefore, we will study the role of these parameters by taking into account the 
fact that the influence of low-intensity EMR is weak. In this case, we use trial values for 
expLγ′  and exp2Iα  assuming that Lγ′  and 2Iα  are only slightly increased under exposure (by 
2% and 4%, respectively, see Table 1). As an additional criterion, the interval of variability of 
these parameters should be chosen in such a way to prevent the system from passing to the 
region III where the regime of dormant tumor is realized (see Figure 4(b)). 
We present numerical results for two parameter sets M1 and M2 (see Table 1) to illustrate 
the body specific effects of electromagnetic radiation. Figure 5 shows bifurcation diagrams 
for both M1 and M2. As is seen, in both cases the system is located in the region of the strong 
immune response. Hence the outcome of disease depends on the initial conditions. We 
assume the same initial numbers of tumor cells and CTL whereas the initial concentration of 
IL-2 for M1 is taken to be higher than for M2. In this case, the remission of tumor for M1 and 
progressive growth for M2 are found (see Figure 6 and 7). As is seen from Figure 6, without 
exposure the dynamical curves for M1 have a character of dumping oscillations. The tumor 
decreases to a small size corresponding to the stable spiral. Although the tumor growth is 
handled by the immune system, for the first 20 days the tumor size is high enough (Figure 
6(a)). As a result, the IL-2 concentration is smaller than its initial value during this period 
(Figure 6(c)). At the same time the population of CTL increases (Figure 6(b)). The results 
show that tumor cells stimulate immune response. This qualitatively agrees with the 
experimental results [17] where both the decrease of the IL-2 concentration and the increase 
of the number of CTL were observed in 20 days of tumor growth.  
Figure 6(a) shows that after exposure to weak RF electromagnetic waves during 20 days 
the tumor size becomes smaller than in the case without exposure. The concentration of IL-2 
markedly increases and reaches the initial value on 20th day (Figure 6(c)). Accordingly, the 
population of CTL also grows up to a larger value in comparison with the case without 
exposure (Figure 6(b)). Thus, our results show that the concentration of IL-2 is restored as a 
result of exposure to EMR, which also qualitatively agrees with the experimental observations 
[17]. It should be mentioned that there are some differences between predictions of our model 
and the experiment. For example, in experiment a decrease of the CTL population in 
comparison with unexposed mice was found after 20 days of irradiation instead of the 
increase in our model. It may be that the production of HSP blocking the proliferation is 
responsible for this observation. The dynamics of HSP is not explicitly taken into account in 
our model. 
In the case of M2, without exposure the tumor grows up to the maximum possible value 
(Figure 7(a)). At the same time, the population of CTL and the IL-2 concentration decrease 
(Figures 7(b) and 7(c)). Nevertheless, initially the tumor stimulates the immune response. 
Hence, the number of CTL on 20th day of tumor growth is higher than their initial value 
(Figure 7(b)). As is seen form Figure 7, after cessation of daily exposure to weak RF EMR 
during 20 days (when the parameters take their normal (initial) values) the dynamical curves 
tend to the stable spiral, and the tumor remission takes place. At the same time, the population 
of CTL and the concentration of IL-2 increase in comparison with unexposed case. Thus, the 
behavior of the IL-2 concentration for M2 also qualitatively agrees with experimental 
observations [17]. It is important that the influence of weak EMR leads to the change of 
dynamical regime from progressive growth to remission of tumor. This follows from the fact 
that the number of tumor cells and CTL as well as the IL-2 concentration fall into the basin of 
attraction of stable spiral after the cessation of exposure. Summarizing, our results show the 
pronounced immunocorrective effect of the weak RF EMR. 
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5 Conclusion 
In this paper, we have formulated the mathematical model for the immune response to the 
malignant growth with the IL-2 taken into account. It is found that tumor growth rate and  the 
level of antigen expression on tumor cells and APC are important factors determining the 
dynamics of disease. Four main dynamical regimes are revealed and shown on the bifurcation 
diagram for antigen presentation by APC. For a low antigen presentation the tumor is able to 
escape from the immune response. In the case of a medium antigen presentation there exist 
two regimens of disease depending on both the initial tumor size and the condition of immune 
system: (i) the regression to small tumor when the dynamical equilibrium is established and 
(ii) a progressive tumor growth to the highest possible size. For a high antigen presentation 
the decrease of the tumor size is found when the equilibrium between the tumor and the 
immune system is established. Additionally, the regime of oscillations in small tumor size, 
number of CTL and the concentration of IL-2 is observed due to the presence of stable limit 
cycle. It is important to note that the regime of full tumor regression as a result of the immune 
response alone is not admitted within our model. This fact is in agreement with clinical 
observations where spontaneous regression of tumors is not possible. 
In order to illustrate the behavior of the system with the effects of weak RF EMR taken 
into account we have chosen two parameter sets so that the system is located in the region II 
of bifurcation diagram where the result of immune response depends on initial tumor size and 
the immune system condition. Namely in this region the system is most sensitive to 
perturbation of the model parameters. We have considered the influence of two model 
parameters characterizing both the rate of inactivation of tumor cells by cytotoxic T cells and 
the production of IL-2. Our results show the marked immunocorrective effect of weak RF 
EMR. In particular, an increase of the IL-2 concentration in comparison with unexposed case 
and enhancement of the immune response are found. Moreover, it may be expected that the 
RF EMR at low intensity is low-toxic. Indeed, we found only minor increase of the IL-2 
concentration which does not exceed the norm. Nevertheless, the frequency range, intensity, 
and other EMR parameters as well as the regimen of exposure should be carefully estimated 
to avoid the harmful influence of EMR on the central nervous, cardiovascular and other 
systems of the body.  
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Table caption 
Table 1. Parameter sets 
Value Parameter Units Description M1 M2 Source 
  
0.22 αT day−1 Tumor growth rate 
  
Fit to data [34] 
  
8.4×10−8 βT cell−1day−1 aξ/bξ is tumor carrying capacity 
  
Fit to data [34] 
Lγ′  cell−1 day−1 
Rate of tumor cells inactivation 
by CTL 4×10
−7
 2.8×10−7  
expLγ′    4.08×10−7 2.86×10−7  
  
7.9×104 VL cell day−1 Rate of steady inflow of CTL 
  
Estimated 
using [35], [36] 
αL cell−1 day−1 
CTL proliferation rate induced 
by IL-2 9.9×10
−9
 1.12×10-8  
  
0.33 βL day−1 CTL death rate 
  
Estimated from 
[37] 
  
1.25×107 2Iα  unit day
−1
 
Antigen presentation 
  
 
exp2Iα    1.3×10
7
 
 
  
6.6×10−8 Lα~  cell−1 day−1 
Rate of consumption of IL-2 by 
CTL 
  
 
γT cell−1 day−1 
Inactivation of IL-2 molecules 
by prostaglandines 6.6×10
−7
 5.5×10−7  
KT cell Half-saturation constant 5.2×104 1×105  
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Figure Captions 
Figure 1. A scheme of the T cell mediated immune response.  
 
Figure 2. The bifurcation diagram varying the antigen presentation (h6). For h6 < h6min there is only one steady 
state — improper node (region I). When h6min < h6 < h6max there are two stable steady states — improper node 
and spiral as well as an unstable (saddle) point (region II). For h6 > h6max only one steady state, the stable spiral 
remains (region III). For h6 > HB the stable spiral passes to the stable limit cycle. 
 
Figure 3. The sensitivity analysis for the parameter set M1 in Table1. The tumor size is more sensitive to tumor 
growth rate variable a, to CTL death rate f, to inactivation of tumor cells by CTL c, to antigen presentation g, to 
CTL proliferation variable e as well as to the rate of inactivation of the IL-2 molecules by prostaglandins k. 
 
Figure 4. The bifurcation diagram h6 vs h1 (a). The bifurcation diagram h6 vs h3 and the variation of steady state 
regime under exposure to low-intensive RF EMR (b). Region I – weak immune response, region II – strong 
immune response, and region III – dormant tumor. 
 
Figure 5. Bifurcation diagrams showing the steady state regimes for the model parameter sets M1 and M2. 
 
Figure 6. Effects of low-intensive RF EMR: (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs time for the 
parameter set M1. The irradiation occurs during 20 days. Initial conditions: 2×105 tumor cells, 2.4×105 cytotoxic 
T lymphocytes, 3.6×107 IL-2 units. 
 
Figure 7. Effects of low-intensive RF EMR: (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs time for the 
parameter set M2. The irradiation occurs during 20 days. Initial conditions: 2×105 tumor cells, 2.4×105 cytotoxic 
T lymphocytes, 2.4×107 IL-2 units. 
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